Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture.
about
Potential pharmacokinetic interactions between antiretrovirals and medicinal plants used as complementary and African traditional medicinesChanges in clearance, volume and bioavailability of immunosuppressants when given with HAART in HIV-1 infected liver and kidney transplant recipients.Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitorsNo evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.Effect of Host Genetic Variation on the Pharmacokinetics and Clinical Response of Non-nucleoside Reverse Transcriptase Inhibitors.ABCB1 variation and treatment response in AIDS patients: initial results of the Henan cohortSucralose, a synthetic organochlorine sweetener: overview of biological issuesSensitive enzyme immunoassay for measuring plasma and intracellular nevirapine levels in human immunodeficiency virus-infected patientsPharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers.Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implicationsP glycoprotein in human immunodeficiency virus type 1 infection and therapy.Editorial neuroAIDS review.The implications of P-glycoprotein in HIV: friend or foe?Drug-transporter mediated interactions between anthelminthic and antiretroviral drugs across the Caco-2 cell monolayers.Therapeutic drug monitoring and human immunodeficiency virus (HIV) antiretroviral therapy.Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamicsCompartment-specific gene regulation of the CAR inducer efavirenz in vivo.Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 StudyThe transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research.The impact of pharmacogenetics on HIV therapy.Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women.A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans.Pharmacometric characterization of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected children.ABC transporters in human lymphocytes: expression, activity and role, modulating factors and consequences for antiretroviral therapies.Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics.The effect of ABCB1 genetic variants on chemotherapy response in HIV and cancer treatment.How much do antiretroviral drugs penetrate into the central nervous system?Immunosuppressive drug therapy--biopharmaceutical challenges and remedies.HIV/AIDS patients display lower relative bioavailability of efavirenz than healthy subjects.Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs.Consequences of a Chronic Exposure of Cultured Brain Astrocytes to the Anti-Retroviral Drug Efavirenz and its Primary Metabolite 8-Hydroxy Efavirenz.Liquid chromatography-mass spectrometry methods for the intracellular determination of drugs and their metabolites: a focus on antiviral drugs.Combination of tenofovir and emtricitabine plus efavirenz: in vitro modulation of ABC transporter and intracellular drug accumulation.Quantitative immunoassay to measure plasma and intracellular atazanavir levels: analysis of drug accumulation in cultured T cells.The relationships of ABCB1 3435C>T and CYP2B6 516G>T with high-density lipoprotein cholesterol in HIV-infected patients receiving Efavirenz.High levels of P-glycoprotein activity in human lymphocytes in the first 6 months of life.Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro-in vivo correlation.Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy subjects.Classification analysis of P-glycoprotein substrate specificity.Population pharmacokinetic model to analyze nevirapine multiple-peaks profile after a single oral dose.
P2860
Q28251303-55F3D930-503D-44BD-9C71-5EC3128AB3BBQ33599107-04122894-44E7-4E57-A103-D0F9FF6FACBDQ33864976-39EBF2E0-173B-4579-A3D9-F716AFF35898Q34151189-1AB615C6-66A5-47F4-AE9F-F2AD1918EA9AQ34443184-7B206DEC-2E07-400B-8BE7-1A74F243F1AEQ34571645-5D915902-B50A-4AC4-9306-2C41DC0E83C3Q34657381-EFBF174F-96B9-4516-9107-EDCD1A2193BDQ35006387-1007785D-6F87-490E-A4D4-28CDB7F5807AQ35018246-78B4B792-B3AA-44B7-87C1-CAEFCD8A6886Q35286119-65E2F2A6-0252-4CDA-BB9E-8E3DDF9BD029Q35718765-14D1F466-79F1-4970-A39A-A53247A06B64Q35731648-E0428177-7D2F-4232-8FB3-4C33E8D411B5Q36135586-CD00D103-05E3-4288-8272-6922EFC720BDQ36362462-2AF1A236-9129-46E5-8852-F83AC91BB977Q36376533-004A3CF8-1568-4A1D-BE85-B6F752354693Q36693543-2B4A546C-B5F8-492C-8437-DE89C7B6904DQ36887151-0BA93B04-0333-40A2-94C1-B9B0764DC377Q37026878-A0248429-12F2-485D-BEF3-CD76E27A7987Q37379470-5FB5F357-13D9-468C-8E19-DBA1B8CB3C5CQ37405140-6F111D18-27FA-4B95-9672-D92096ECE134Q37417511-C53F35DE-7A41-46AC-8B70-89DA6386B013Q37471061-9D427A46-0E2F-48E0-AB9D-4448668682BCQ37544540-583E4B97-3E0F-4D57-9883-8C48C5CE359DQ37724178-FE49B599-76E1-4955-B35B-AB320B77DB16Q37866298-7545F0D2-7D6D-4909-85B6-B05E5B1865D4Q37946959-56B3EAD9-0DA0-4EAC-8CFE-D13C2BF2DA22Q38003612-B84CF793-05DD-4095-9CAF-0E294988392AQ38340831-CFD31F67-1D20-46AC-84EE-557A72854181Q38869853-7220D1C3-FD88-42D4-9803-38664E9239E8Q38957969-A8B30E27-A033-4119-A966-4DC72B704DB8Q39364925-65688882-060D-4C46-8648-ADAF533E44D6Q39434360-1EB36DC4-B6FE-402A-97AB-3E073F3F1629Q41791556-ED32C198-9D7D-4826-B18F-6B70C80A861CQ42956763-21CDEB2F-E44C-4FAA-A03D-73E47BD78491Q45993645-122B3CF5-C103-43A7-BEB5-9AA898164732Q46226197-CC3F3FE9-8959-4C76-B904-7A332C9722E6Q46448056-AC4EAF52-45DB-470C-BA5D-93E57204E909Q46562540-D81965B0-04B8-4512-9F8D-770B7A57554DQ47326688-972554A5-1048-4062-99AA-4CD4AA92D622Q51064185-DE42770C-04B1-4538-8051-C8C191C74B90
P2860
Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Differential modulation of P-g ...... se inhibitors in cell culture.
@en
Differential modulation of P-g ...... se inhibitors in cell culture.
@nl
type
label
Differential modulation of P-g ...... se inhibitors in cell culture.
@en
Differential modulation of P-g ...... se inhibitors in cell culture.
@nl
prefLabel
Differential modulation of P-g ...... se inhibitors in cell culture.
@en
Differential modulation of P-g ...... se inhibitors in cell culture.
@nl
P2093
P356
P1476
Differential modulation of P-g ...... se inhibitors in cell culture.
@en
P2093
David J Greenblatt
Elke Störmer
Lisa L von Moltke
P304
P356
10.1023/A:1016430825740
P577
2002-07-01T00:00:00Z